VRDNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Viridian Therapeutics, Inc.\DE
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$20.80+1.77 (+9.30%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Viridian Therapeutics, Inc.\DE revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q4 21 | TTM Q3 21 | TTM Q2 21 | TTM Q1 21 | TTM Q4 20 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| License | $70.24M | $70.01M | $70.00M | $70.00M | $0 | – | $0 | – | – | – | – | – | 98.8% | – |
| Collaboration | $888.00K | $912.00K | $849.00K | $789.00K | $305.00K | – | $302.00K | – | – | – | – | – | 1.2% | +191.1% |
| Collaboration Revenue | – | – | – | – | – | – | – | $2.96M | $262.00K | $54.00K | $54.00K | $735.00K | – | – |
| Research and development reimbursable costs | – | – | – | – | – | – | – | – | – | – | – | $681.00K | – | – |
| Grant revenue | – | – | – | – | – | – | – | $0 | $0 | $0 | $168.00K | $315.00K | – | – |
By region
From the segment and revenue-disaggregation notes of Viridian Therapeutics, Inc.\DE's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.